Protocol Ledger

NCT06583486 · Phase III · COMPLETED

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Interventional Phase III clinical trial protocol NCT06583486 sponsored by Chongqing Claruvis Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-19 Enrollment: 488 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06583486
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)488 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06583486
Protocol FieldVerified Registry Value
NCT IdentifierNCT06583486
Consolidated Lead SponsorChongqing Claruvis Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment488 participants (ACTUAL)
Registered Start Date2024-03-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI